ST吉药(300108) - 2024 Q1 - 季度财报

Financial Performance - Revenue for Q1 2024 was CNY 75,460,849.87, an increase of 5.36% compared to CNY 71,621,163.94 in the same period last year[5]. - Net loss attributable to shareholders was CNY -40,853,954.75, representing a decline of 101.93% from CNY -20,231,788.56 year-over-year[5]. - Net loss for Q1 2024 was CNY 60,502,670.21, compared to a net loss of CNY 30,964,687.78 in the same period last year, indicating a worsening of 95.5%[18]. - The total comprehensive income for the first quarter of 2024 was -60,502,670.21 CNY, compared to -30,964,687.78 CNY in the same period last year, indicating a decline of approximately 95%[19]. - The company’s total comprehensive income attributable to the parent company was -40,853,954.75 CNY, compared to -20,231,788.56 CNY in the same period last year, reflecting a decline of approximately 102%[19]. Cash Flow and Liquidity - Net cash flow from operating activities improved to CNY 1,073,613.47, a significant increase of 115.53% compared to CNY -6,914,375.11 in the previous year[5]. - Cash inflow from operating activities totaled 78,413,126.79 CNY, up from 68,110,533.31 CNY, reflecting an increase of about 3.9%[21]. - Cash and cash equivalents at the end of the period increased to 26,700,040.88 CNY from 11,732,220.95 CNY, marking a rise of approximately 128%[22]. - The net cash flow from investing activities was -195,205.08 CNY, slightly better than -260,050.00 CNY in the previous year[22]. - The company received 3,997,097.85 CNY from financing activities, a recovery from -4,410,387.77 CNY in the previous year[22]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,892,261,004.60, a decrease of 1.13% from CNY 1,913,801,546.81 at the end of the previous year[5]. - Total liabilities increased to CNY 2,759,896,956.40 from CNY 2,720,934,828.40, marking a rise of 1.4%[15]. - The company's equity attributable to shareholders decreased to CNY -321,525,846.02 from CNY -280,671,891.27, indicating a decline in shareholder equity[15]. Operational Metrics - Total operating revenue for Q1 2024 was CNY 75,460,849.87, an increase of 5.2% compared to CNY 71,621,163.94 in the previous period[17]. - Total operating costs decreased slightly to CNY 126,726,415.45 from CNY 127,061,747.57, with operating costs specifically down to CNY 51,531,566.54 from CNY 57,436,793.67, reflecting a reduction of 10.3%[17]. - The company reported a significant increase in financial expenses, totaling CNY 38,707,439.57, compared to CNY 37,287,430.41 in the previous period[18]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 20,338[10]. - The company reported a basic and diluted earnings per share of -0.0613 CNY, worsening from -0.0304 CNY year-over-year[19]. Other Information - The company recorded non-operating losses of CNY -2,910,380.42, primarily due to financing lease penalties and tax penalties[6]. - The company has not disclosed any new product developments or market expansion strategies in this report[12]. - The company reported a decrease in accounts receivable financing by 31.50%, from CNY 13,891,226.35 to CNY 9,515,159.40[8]. - Contract liabilities increased by 31.44%, from CNY 28,286,614.84 to CNY 37,178,929.67, indicating a rise in received advance payments[8]. - Accounts receivable increased to CNY 142,727,678.61 from CNY 137,147,590.91, reflecting a growth of 4.2%[14]. - Inventory decreased to CNY 115,609,898.09 from CNY 116,440,299.16, a decline of 0.7%[14]. - Cash and cash equivalents slightly decreased to CNY 27,511,513.97 from CNY 27,608,851.25, a reduction of 0.4%[14].